+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Regenerative Medicine Market Size, Share & Trends Analysis Report by Product (Primary Cell-based Therapeutics, Stem Cell & Progenitor Cell-based Therapeutics), Therapeutic Category (Dermatology, Musculoskeletal), Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 230 Pages
  • November 2023
  • Region: Global
  • Grand View Research
  • ID: 4375420
The global regenerative medicine market size is expected to reach USD 90.01 billion by 2030, expanding at a CAGR of 16.79% from 2024 to 2030, according to the report. The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson’s disease treatment. This approval was expected to expand the company’s offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Report Highlights

  • The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
  • The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
  • Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
  • North America dominated the market in 2023 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
  • Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
  • By therapeutic category, the oncology segment dominated the segment in 2023 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth.


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Information analysis
1.2.2. Market formulation & data visualization
1.2.3. Data validation & publishing
1.3. Information Procurement
1.3.1. Primary Others
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Market Model
1.7. Objectives
1.7.1. Objective 1
1.7.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Presence of a strong pipeline and a large number of clinical trials
3.3.2. High economic impact of regenerative medicine
3.3.3. Emerging applications of gene therapy in regenerative medicine
3.3.4. Increasing government & private funding to support the development of regenerative medicine
3.3.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
3.3.6. Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
3.3.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
3.4. Market Restraint Analysis
3.4.1. High cost of treatment
3.4.2. Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Global Regenerative Medicine Market: Product Movement Analysis
4.2. Therapeutics
4.2.1. Therapeutics Market, 2018 - 2030 (USD Million)
4.2.2. Primary Cell-Based Therapeutics
4.2.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
4.2.2.2. Dermatology
4.2.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
4.2.2.3. Musculoskeletal
4.2.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
4.2.2.4. Surgical
4.2.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
4.2.2.5. Dental
4.2.2.5.1. Dental Market, 2018 - 2030 (USD Million)
4.2.2.6. Others
4.2.2.6.1. Others Market, 2018 - 2030 (USD Million)
4.2.3. Stem Cell & Progenitor Cell-based therapeutics
4.2.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
4.2.3.2. Autologous
4.2.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
4.2.3.3. Allogenic
4.2.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
4.2.3.4. Others
4.2.3.5. Others Market, 2018 - 2030 (USD Million)
4.2.4. Cell-based Immunotherapies
4.2.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
4.2.5. Gene Therapies
4.2.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
4.3. Tools
4.3.1. Tools Market, 2018 - 2030 (USD Million)
4.4. Banks
4.4.1. Banks Market, 2018 - 2030 (USD Million)
4.5. Services
4.5.1. Services Market, 2018 - 2030 (USD Million)
Chapter 5. Therapeutic Category Business Analysis
5.1. Global Regenerative Medicine Market: Therapeutic Category Movement Analysis
5.2. Dermatology
5.2.1. Dermatology Market, 2018 - 2030 (USD Million)
5.3. Musculoskeletal
5.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
5.4. Immunology & Inflammation
5.4.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
5.5. Oncology
5.5.1. Oncology Market, 2018 - 2030 (USD Million)
5.6. Cardiovascular
5.6.1. Cardiovascular Market, 2018 - 2030 (USD Million)
5.7. Ophthalmology
5.7.1. Ophthalmology Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Global Regenerative Medicine Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Competitive Scenario
6.2.2.3. Regulatory Framework
6.2.2.4. Target Disease Prevalence
6.2.2.5. U.S. Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Competitive Scenario
6.2.3.3. Regulatory Framework
6.2.3.4. Target Disease Prevalence
6.2.3.5. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.2. Germany
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. Target Disease Prevalence
6.3.2.5. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.3. UK
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Target Disease Prevalence
6.3.3.5. UK Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. Target Disease Prevalence
6.3.4.5. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Competitive Scenario
6.3.5.3. Regulatory Framework
6.3.5.4. Target Disease Prevalence
6.3.5.5. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Competitive Scenario
6.3.6.3. Regulatory Framework
6.3.6.4. Target Disease Prevalence
6.3.6.5. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Competitive Scenario
6.3.7.3. Regulatory Framework
6.3.7.4. Target Disease Prevalence
6.3.7.5. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Competitive Scenario
6.3.8.3. Regulatory Framework
6.3.8.4. Target Disease Prevalence
6.3.8.5. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Competitive Scenario
6.3.9.3. Regulatory Framework
6.3.9.4. Target Disease Prevalence
6.3.9.5. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. Target Disease Prevalence
6.4.2.5. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Target Disease Prevalence
6.4.3.5. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. Target Disease Prevalence
6.4.4.5. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.5. South Korea
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Target Disease Prevalence
6.4.5.5. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.6. Australia
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Target Disease Prevalence
6.4.6.5. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Target Disease Prevalence
6.4.7.5. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Target Disease Prevalence
6.5.2.5. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Target Disease Prevalence
6.5.3.5. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.5.4. Argentina
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. Target Disease Prevalence
6.5.4.5. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Target Disease Prevalence
6.6.2.5. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Target Disease Prevalence
6.6.3.5. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Target Disease Prevalence
6.6.4.5. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Target Disease Prevalence
6.6.5.5. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market/Position Share Analysis, 2022
7.4. Company Profiles/Listing
7.4.1. AstraZeneca plc.
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. F. Hoffmann-La Roche Ltd.
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Integra Lifesciences Corp.
7.4.3.1. Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Astellas Pharma, Inc.
7.4.4.1. Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Cook Biotech, Inc.
7.4.5.1. Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Bayer AG
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Pfizer, Inc.
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Merck KGaA
7.4.8.1. Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Abbott
7.4.9.1. Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Vericel Corp.
7.4.10.1. Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Novartis AG
7.4.11.1. Overview
7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. GlaxoSmithKline
7.4.12.1. Overview
7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.12.3. Product Benchmarking
7.4.12.4. Strategic Initiatives
List of Tables
Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 Global Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 4 Global Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 5 North America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 6 North America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 7 North America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 8 U.S. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 9 U.S. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 10 Canada Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 11 Canada Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 12 Europe Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 13 Europe Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 14 Europe Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 15 Germany Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 16 Germany Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 17 U.K. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 18 U.K. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 19 France Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 20 France Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 21 Italy Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 22 Italy Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 23 Spain Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 24 Spain Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 25 Denmark Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 26 Denmark Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 27 Norway Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 28 Norway Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 29 Sweden Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 30 Sweden Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 31 Asia Pacific Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 32 Asia Pacific Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 33 Asia Pacific Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 34 China Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 35 China Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 36 Japan Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 37 Japan Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 38 India Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 39 India Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 40 Australia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 41 Australia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 42 South Korea Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 43 South Korea Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
Table 44 Thailand Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 45 Thailand Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
Table 46 Latin America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 47 Latin America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 48 Latin America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 49 Brazil Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 50 Brazil Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 51 Mexico Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 52 Mexico Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 53 Argentina Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 54 Argentina Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 55 Middle East & Africa Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 58 South Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 59 South Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 62 UAE Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 63 UAE Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 64 Kuwait Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 65 Kuwait Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 66 Participant’s Overview
Table 67 Financial Performance
Table 68 Key Companies Undergoing Expansions
Table 69 Key Companies Undergoing Acquisitions
Table 70 Key Companies Undergoing Collaborations
Table 71 Key Companies Launching New Products/Services
Table 72 Key Companies Undergoing Partnerships
Table 73 Key Companies Undertaking Other Strategies
List of Figures
Fig. 1 Market Others process
Fig. 2 Data triangulation techniques
Fig. 3 Primary Others pattern
Fig. 4 Market Others approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market summary, 2023 (USD Million)
Fig. 9 Market segmentation & scope
Fig. 10 Market driver impact
Fig. 11 Market restraint impact
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Porter’s analysis
Fig. 14 SWOT analysis
Fig. 15 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
Fig. 16 Global primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 17 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 18 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 19 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 20 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 21 Global other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 22 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 23 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 24 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 25 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 26 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
Fig. 27 Global gene therapies market, 2018 - 2030 (USD Million)
Fig. 28 Global regenerative medicines tools, 2018 - 2030 (USD Million)
Fig. 29 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
Fig. 30 Global regenerative medicine services market, 2018 - 2030 (USD Million)
Fig. 31 Regenerative medicine market: Therapeutic category outlook and key takeaways
Fig. 32 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
Fig. 33 Global dermatological therapeutics category market, 2018 - 2030 (USD Million)
Fig. 34 Global musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
Fig. 35 Global immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
Fig. 36 Global oncology therapeutics category market, 2018 - 2030 (USD Million)
Fig. 37 Global cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
Fig. 38 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
Fig. 39 Global other therapeutics category market, 2018 - 2030 (USD Million)
Fig. 40 Global Regenerative Medicine Market: Regional outlook and key takeaways
Fig. 41 North America Regenerative Medicine Market, 2018 - 2030 (USD million)
Fig. 42 U.S. key country dynamics
Fig. 43 U.S. Regenerative Medicine Market, 2018 - 2030 (USD million)
Fig. 44 Canada key country dynamics
Fig. 45 Canada Regenerative Medicine Market, 2018 - 2030 (USD million)
Fig. 46 Europe Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Germany key country dynamics
Fig. 48 Germany Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 France key country dynamics
Fig. 50 France Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 U.K. key country dynamics
Fig. 52 U.K. Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Italy key country dynamics
Fig. 54 Italy Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Spain key country dynamics
Fig. 56 Spain Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Denmark key country dynamics
Fig. 58 Denmark Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Sweden key country dynamics
Fig. 60 Sweden Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Norway key country dynamics
Fig. 62 Norway Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Asia-Pacific Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 China key country dynamics
Fig. 65 China Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 India key country dynamics
Fig. 67 India Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 South Korea key country dynamics
Fig. 69 South Korea Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Japan key country dynamics
Fig. 71 Japan Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Australia key country dynamics
Fig. 73 Australia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Thailand key country dynamics
Fig. 75 Thailand Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Latin America Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Brazil key country dynamics
Fig. 78 Brazil Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Mexico key country dynamics
Fig. 80 Mexico Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Argentina key country dynamics
Fig. 82 Argentina Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 MEA Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 South Africa key country dynamics
Fig. 85 South Africa Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 Saudi Arabia key country dynamics
Fig. 87 Saudi Arabia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 UAE key country dynamics
Fig. 89 UAE Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 Kuwait key country dynamics
Fig. 91 Kuwait Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Market participant categorization
Fig. 93 Regenerative Medicine Market share analysis, 2023
Fig. 94 Strategy framework

Companies Profiled

  • AstraZeneca plc.
  • F. Hoffmann-La Roche Ltd.
  • Integra Lifesciences Corp.
  • Astellas Pharma, Inc.
  • Cook Biotech, Inc.
  • Bayer AG
  • Pfizer, Inc.
  • Merck KGaA
  • Abbott
  • Vericel Corp.
  • Novartis AG
  • GlaxoSmithKline

Methodology

Loading
LOADING...

Table Information